Broyhill Asset Management Makes New $231,000 Investment in Pfizer Inc. (NYSE:PFE)

Broyhill Asset Management acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 8,700 shares of the biopharmaceutical company’s stock, valued at approximately $231,000.

Other hedge funds also recently made changes to their positions in the company. Retirement Wealth Solutions LLC bought a new stake in Pfizer during the fourth quarter worth about $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer in the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer in the fourth quarter worth approximately $28,000. Noble Wealth Management PBC bought a new position in Pfizer during the fourth quarter valued at approximately $31,000. Finally, Bernard Wealth Management Corp. purchased a new position in shares of Pfizer during the fourth quarter worth approximately $33,000. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. UBS Group reduced their target price on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a report on Tuesday, April 8th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $31.07.

Pfizer Price Performance

Shares of PFE opened at $21.89 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market cap of $124.14 billion, a PE ratio of 15.52, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The firm’s 50-day simple moving average is $25.25 and its two-hundred day simple moving average is $26.38. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the business earned $0.10 EPS. Pfizer’s revenue was up 24.7% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.